173 related articles for article (PubMed ID: 23023138)
1. Clinical performance characteristics of the Cervista HPV HR test kit in cervical cancer screening in China.
Zhao J; Zhang X; Ma J; Liu G; Yao D; Zhang W; Wang J; Wei L; Zhao Y; Zeng Y; Liao Q
J Low Genit Tract Dis; 2012 Oct; 16(4):358-63. PubMed ID: 23023138
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of The Cervista HPV A9 group In Screening Patients for Cervical Cancer.
Zhao J; Du H; Belinson JL; Qu X; Zhang W; Mei J; Yang B; Wang C; Zhang L; Wu R
J Med Screen; 2016 Mar; 23(1):38-43. PubMed ID: 26466824
[TBL] [Abstract][Full Text] [Related]
3. [Clinical value of p16
Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
[No Abstract] [Full Text] [Related]
4. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
6. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
Zhang H; Varma KR; Han M; Matsko J; Zhao C
Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women.
Tuerxun G; Yukesaier A; Lu L; Aierken K; Mijiti P; Jiang Y; Abulizi A; Zhang Y; Abuduxikuer G; Abulizi G; Li H
Oncologist; 2016 Jul; 21(7):825-31. PubMed ID: 27317575
[TBL] [Abstract][Full Text] [Related]
8. High-risk human papillomavirus detection in women with low-grade squamous intraepithelial lesions or higher-grade cytology using the Cervista HPV HR test.
Gold MA; Thomas MA; Huh WK; Sarto GE; Day SP
J Low Genit Tract Dis; 2013 Jan; 17(1):51-7. PubMed ID: 22885641
[TBL] [Abstract][Full Text] [Related]
9. A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off.
Boehmer G; Wang L; Iftner A; Holz B; Haedicke J; von Wasielewski R; Martus P; Iftner T
BMC Infect Dis; 2014 Dec; 14():674. PubMed ID: 25487281
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].
Duan LF; Du H; Wang C; Huang X; Qu XF; Duan XZ; Liu Y; Shi B; Zhang W; Wei LH; Belinson L; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Oct; 55(10):708-715. PubMed ID: 33120484
[No Abstract] [Full Text] [Related]
11. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.
Einstein MH; Martens MG; Garcia FA; Ferris DG; Mitchell AL; Day SP; Olson MC
Gynecol Oncol; 2010 Aug; 118(2):116-22. PubMed ID: 20488510
[TBL] [Abstract][Full Text] [Related]
12. Discrepant HPV/cytology cotesting results: Are there differences between cytology-negative versus HPV-negative cervical intraepithelial neoplasia?
Tracht JM; Davis AD; Fasciano DN; Eltoum IA
Cancer Cytopathol; 2017 Oct; 125(10):795-805. PubMed ID: 28817235
[TBL] [Abstract][Full Text] [Related]
13. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
[TBL] [Abstract][Full Text] [Related]
14. Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population.
Alameda F; Garrote L; Mojal S; Sousa C; Muset M; LLoveras B; Bellosillo B; Saldanha C; Carreras R; Serrano S
Arch Pathol Lab Med; 2015 Feb; 139(2):241-4. PubMed ID: 25611107
[TBL] [Abstract][Full Text] [Related]
15. Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
[TBL] [Abstract][Full Text] [Related]
16. Rate of detection of high-risk HPV with two assays in women ≥ 30 years of age.
Quigley NB; Potter NT; Chivukula M; Knight MZ; Welch JR; Olson MC
J Clin Virol; 2011 Sep; 52(1):23-7. PubMed ID: 21724457
[TBL] [Abstract][Full Text] [Related]
17. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
18. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
19. Cervista HPV HR test kit in cervical cancer screening.
Wiwanitkit V
J Low Genit Tract Dis; 2013 Jan; 17(1):99. PubMed ID: 23222057
[No Abstract] [Full Text] [Related]
20. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
